|
| A Meta-analysis on randomized controlled trials of routine Western medical treatment plus Buyi Qiangxin tablet for treating chronic heart failure |
| Hits 1485 Download times 1266 Received:June 24, 2018 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2018.12.13 |
| Key Words
Buyi Qiangxin tablet;chronic heart failure;randomized controlled trial;Meta-analysis |
| Author Name | Affiliation | E-mail | | MO Xinyu | Qiannan Medical College for Nationalities, Duyun 558000, China | | | WANG Xianliang | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | xlwang1981@126.com | | HOU Yazhu | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | | | BI Yingfei | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | | | MAO Jingyuan | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | |
|
| Abstract
|
| [Objective] To systematically review the safety and efficacy of routine Western medical treatment plus Buyi Qiangxin tablets for treating patients with chronic heart failure(CHF).[Methods] CNKI, VIP, Wanfang Data, SinoMed, PubMed, Embase, Web of Science and Cochrane Library(Issue 3, 2018) were retrieved by computer for papers on randomized control trials (RCTs) of treating CHF patients by routine Western medical treatment plus Buyi Qiangxin tablets, which were searched from inception to Mar. 2018. The quality of inclusive literatures was assessed by methods from Cochrane Handbook. Valid data were extracted and analyzed by Meta-analysis using RevMan 5.3.5 Software.[Results] There were totally 7 trials and 573 cases in line with standard were included. Results of Meta-analysis showed, compared with the routine Western medical treatment group, additional use of Buyi Qiangxin Tablets could increase left ventricular ejection fraction (LVEF)[MD=4.31,95%CI(3.73, 4.90), P<0.000 01], reduce the level of NT-proBNP[SMD=-2.02, 95%CI (-3.02, -1.02),P<0.000 1], improve the cardiac function(NYHA)[RR=1.25, 95%CI(1.09, 1.43),P=0.001],drop the score of Lee's heart failure[MD=-1.09,95%CI(-1.36, -0.83),P<0.000 01] and Minnesota life quality of heart failure questionnaires(MLHFQ)[MD=-10.90, 95%CI(13.12, -8.68),P<0.000 01].[Conclusion] Research result showed routine Western medical treatment plus Buyi Qiangxin tablets is safe and could further improve the cardiac function, clinical symptom and quality of life. However, due to the qualities of overall literatures are lower and lack of evidence, the conclusions are needed to be validated by more large samples of high quality clinical research. |
|
|
|
|
|
|
|
